The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Documenti analoghi

• Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
  di: Ziouti, Fani, et al.
  Pubblicazione: (2021)
• Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma
  di: Rosich, Laia, et al.
  Pubblicazione: (2013)
• Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
  di: Montraveta, Arnau, et al.
  Pubblicazione: (2015)
• Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
  di: Brown, Jennifer R., et al.
  Pubblicazione: (2016)
• Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
  di: Owen, C., et al.
  Pubblicazione: (2019)